Twist Bioscience (TWST) Set to Post Quarterly Earnings on Thursday

Twist Bioscience (NASDAQ:TWST) is expected to release its Q4 2026 results before the market opens on Thursday, November 12th. Analysts expect the company to announce earnings of ($0.3845) per share and revenue of $123.55 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2026 earnings report for the latest details on the call scheduled for Thursday, November 12, 2026 at 8:00 AM ET.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Monday, August 3rd. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.05). Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. The business had revenue of $118.38 million during the quarter, compared to analysts’ expectations of $114.55 million. During the same quarter last year, the firm earned $0.33 earnings per share. The firm’s quarterly revenue was up 23.2% compared to the same quarter last year. On average, analysts expect Twist Bioscience to post ($2.12) EPS for the current fiscal year and ($1.56) EPS for the next fiscal year.

Twist Bioscience Stock Up 1.6%

Shares of TWST opened at $142.58 on Thursday. The stock has a 50 day moving average price of $152.59 and a 200 day moving average price of $90.28. Twist Bioscience has a one year low of $23.30 and a one year high of $219.71. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.38 and a current ratio of 2.67. The stock has a market capitalization of $8.94 billion, a price-to-earnings ratio of -64.22 and a beta of 2.25.

Analysts Set New Price Targets

TWST has been the topic of several recent research reports. Jefferies Financial Group began coverage on shares of Twist Bioscience in a research note on Thursday, October 8th. They set a “hold” rating and a $150.00 target price on the stock. Robert W. Baird increased their target price on shares of Twist Bioscience from $113.00 to $115.00 and gave the company an “outperform” rating in a research report on Tuesday, August 4th. Barclays raised their price target on shares of Twist Bioscience from $112.00 to $215.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 7th. Guggenheim boosted their price target on shares of Twist Bioscience from $107.00 to $212.00 and gave the stock a “buy” rating in a research report on Thursday, October 1st. Finally, UBS Group initiated coverage on shares of Twist Bioscience in a research note on Wednesday, September 9th. They set a “neutral” rating and a $144.00 price objective for the company. Seven equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $153.00.

Insiders Place Their Bets

In related news, CFO Adam Laponis sold 2,462 shares of Twist Bioscience stock in a transaction that occurred on Friday, October 9th. The shares were sold at an average price of $156.30, for a total value of $384,810.60. Following the completion of the transaction, the chief financial officer owned 98,114 shares in the company, valued at $15,335,218.20. The trade was a 2.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Emily Leproust sold 4,548 shares of the business’s stock in a transaction that occurred on Monday, October 5th. The stock was sold at an average price of $202.15, for a total transaction of $919,378.20. Following the transaction, the chief executive officer owned 562,760 shares of the company’s stock, valued at $113,761,934. This trade represents a 0.80% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 601,920 shares of company stock valued at $93,768,202. 3.08% of the stock is owned by company insiders.

About Twist Bioscience

Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA and related products for life sciences research. The company uses a proprietary silicon-based platform to produce high-quality DNA at scale, supporting applications in synthetic biology, drug discovery and development, agriculture, and academic and industrial research.

Its offerings include synthetic genes, oligonucleotides, gene fragments, variant libraries, and antibody discovery products.